Limitations: In one half of the trials, fewer than 50% of the
potentially eligible patients were randomly assigned. Only 5 trials
were considered high quality, and only 2 were conducted in the
United States. No studies addressed whether PST or PSM is safe
during the high-risk initiation phase.